Suggested Topics within your search.
Showing 241 - 260 results of 2,535 for search '"Poole"', query time: 0.05s Refine Results
  1. 241
  2. 242
  3. 243
  4. 244
  5. 245
  6. 246
  7. 247

    Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis by Andrew Blauvelt, Leon Kircik, Todd Schlesinger, Evangeline Pierce, Russel Burge, Michael Behling, Amber Reck Atwater, Hany ElMaraghy, April Armstrong

    Published 2025-12-01
    “…Background Lebrikizumab monotherapy significantly improved signs and symptoms in patients with moderate-to-severe atopic dermatitis (AD) in phase 3 Advocate1 and ADvocate2 studies.Objective To evaluate improvements in patient-reported symptoms and quality-of-life (QoL) measures by Eczema Area and Severity Index (EASI) response categories using pooled Advocate1 and ADvocate2 data (post hoc analysis).Methods In the 52-week (W) (16-W induction + 36-W maintenance) double-blind, placebo-controlled ADvocate1 and ADvocate2 studies, patients were randomized (2:1) to receive subcutaneous lebrikizumab 250 mg or placebo every 2 weeks. …”
    Get full text
    Article
  8. 248
  9. 249
  10. 250
  11. 251
  12. 252
  13. 253
  14. 254
  15. 255
  16. 256
  17. 257
  18. 258
  19. 259
  20. 260